- Home
- CHI vs KALV Comparison
CHI vs KALV Comparison
Compare CHI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | KALV |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHI | KALV |
|---|---|---|
| Price | $12.72 | $26.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 165.1K | ★ 3.9M |
| Earning Date | 01-01-0001 | 07-09-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $10.00 | $9.83 |
| 52 Week High | $12.75 | $26.85 |
Technical Indicators
Market Signals| Indicator | CHI | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 74.40 |
| Support Level | $10.84 | $14.22 |
| Resistance Level | N/A | $26.85 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 97.28 | 85.29 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.